Back

Deletion of fibroblast activation protein decreases experimental atherosclerotic plaque formation and vulnerability

31 August 2019 (11:00 - 16:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Atherosclerosis and vascular dysfunction Vascular Diseases: Fibrosis ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Sokrates Stein

University of Zurich, Zurich (Switzerland)

12 More presentations in this session

Presentation thumbnail
Associate Professor I. Khripun (Rostov-on-Don, RU)
Abstract Slides
Presentation thumbnail
Doctor M. Oguri (Kasugai, JP)
Abstract Slides
Presentation thumbnail
Doctor N. Karamichalakis (Athens, GR)
Abstract Slides
Presentation thumbnail
Miss A. Sakic (Geneva, CH)
Abstract
Presentation thumbnail
Doctor L. Xu (Shanghai, CN)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Atherosclerosis and vascular dysfunction

The Event

Event poster

ESC Congress 2019

31 August 2019 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Effect of 5-lipoxygenase-activating protein inhibiton on coronary atherosclerosis progression in patients with recent acute coronary syndrome: the PASSIVATE randomised clinical trial
1 September 2025
thumbnail
Congress Presentation
Macrophage-specific IRF5 deficiency stabilizes atherosclerotic plaques in ApoE-/- mice
31 August 2020
thumbnail
Congress Presentation
The central role of FAP dysregulation and cardiac fibroblast activation in heart failure patients
26 August 2023
thumbnail
Congress Presentation
Feasibility of 68Ga-FAPI-46 PET for evaluating fibrosis activity in aortic aneurysm
20 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources